Atb Cap Markets Cuts Earnings Estimates for Aurora Cannabis

Key Points

• ATB Capital Markets has revised its Q2 2026 earnings per share estimate for Aurora Cannabis from ($0.06) to ($0.07), indicating a more pessimistic outlook for the company.
• Aurora Cannabis reported disappointing earnings for the last quarter, with a loss of ($0.19) EPS compared to the expected gain of $0.18, and revenue of $71.98 million falling short of estimates.
• Wall Street Zen downgraded Aurora Cannabis shares from a "hold" rating to a "sell" rating, reflecting growing concerns over the company's financial performance.

Aurora Cannabis Inc. (NASDAQ:ACB - Free Report) - Investment analysts at Atb Cap Markets cut their Q2 2026 earnings per share estimates for Aurora Cannabis in a research note issued on Wednesday, August 6th. Atb Cap Markets analyst F. Gomes now anticipates that the company will earn ($0.07) per share for the quarter, down from their previous estimate of ($0.06). The consensus estimate for Aurora Cannabis' current full-year earnings is $0.46 per share. Atb Cap Markets also issued estimates for Aurora Cannabis' Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.30 EPS.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.18 by ($0.37). Aurora Cannabis had a negative return on equity of 1.49% and a negative net margin of 5.66%. The firm had revenue of $71.98 million for the quarter, compared to analyst estimates of $96.83 million.

A number of other brokerages also recently commented on ACB. Wall Street Zen downgraded Aurora Cannabis from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Zacks Research raised Aurora Cannabis to a "strong sell" rating in a report on Friday, August 8th. Two analysts have rated the stock with a sell rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Aurora Cannabis currently has a consensus rating of "Moderate Buy".

Aurora Cannabis Stock Down 2.5%

Shares of NASDAQ ACB traded down $0.14 on Monday, hitting $5.25. The company had a trading volume of 522,026 shares, compared to its average volume of 1,905,799. Aurora Cannabis has a 12-month low of $3.42 and a 12-month high of $7.05. The business has a 50 day moving average of $4.78 and a two-hundred day moving average of $4.83. The company has a quick ratio of 1.51, a current ratio of 2.97 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $296.53 million, a P/E ratio of -27.65 and a beta of 1.84.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP raised its stake in Aurora Cannabis by 18.7% during the fourth quarter. Two Sigma Advisers LP now owns 62,100 shares of the company's stock valued at $264,000 after buying an additional 9,793 shares in the last quarter. Millennium Management LLC acquired a new stake in Aurora Cannabis during the fourth quarter valued at approximately $67,000. Dimensional Fund Advisors LP raised its stake in Aurora Cannabis by 7.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 84,921 shares of the company's stock valued at $361,000 after buying an additional 5,800 shares in the last quarter. Renaissance Technologies LLC raised its stake in Aurora Cannabis by 8.6% during the fourth quarter. Renaissance Technologies LLC now owns 714,655 shares of the company's stock valued at $3,037,000 after buying an additional 56,400 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Aurora Cannabis during the fourth quarter valued at approximately $221,000. Hedge funds and other institutional investors own 47.63% of the company's stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.